The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced ...

IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company ...

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard ...

The University of Southern California (USC) has received a $6m grant from the California Institute for Regenerative Medicine ...

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.